189 related articles for article (PubMed ID: 12743128)
41. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer.
Martino MA; Miller E; Grendys EC
Gynecol Oncol; 2005 May; 97(2):710-2. PubMed ID: 15863189
[TBL] [Abstract][Full Text] [Related]
42. Docetaxel/carboplatin combination produces impressive response in ovarian cancer patients.
Oncology (Williston Park); 2001 Jul; 15(7):920. PubMed ID: 11499692
[No Abstract] [Full Text] [Related]
43. Docetaxel: promising and novel combinations in ovarian cancer.
Mäenpää JU
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S29-34. PubMed ID: 14661044
[TBL] [Abstract][Full Text] [Related]
44. [Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer].
Gorbunova VA; Khokhlova SV; Besova NS; Orel NF; Kuznetsov VV; Bliumenberg AG; Smirnova NB; Chekalova MA; Sinitsyna ME; Poddubnyĭ BK
Vopr Onkol; 2001; 47(5):1-6. PubMed ID: 11799946
[No Abstract] [Full Text] [Related]
45. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
46. Advances in the treatment of gynecologic malignancies. Part 2: Cancers of the uterine corpus and ovary.
Kim RY; Omura GA; Alvarez RD
Oncology (Williston Park); 2002 Dec; 16(12):1669-78; discussion 1678-80. PubMed ID: 12520642
[TBL] [Abstract][Full Text] [Related]
47. [Second-line chemotherapy for recurrent ovarian cancer].
Sugiyama T
Gan To Kagaku Ryoho; 2005 Jan; 32(1):28-32. PubMed ID: 15675578
[TBL] [Abstract][Full Text] [Related]
48. Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
Clouse T; Geisler JP; Manahan KJ; Gudenkauf TJ; Linnemeier G; Wiemann MC
Gynecol Oncol; 2004 Oct; 95(1):270-1. PubMed ID: 15385146
[No Abstract] [Full Text] [Related]
49. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
Newman G
Lancet; 2003 Oct; 362(9392):1333; author reply 1334. PubMed ID: 14575996
[No Abstract] [Full Text] [Related]
50. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
Kavanagh J; Tresukosol D; Edwards C; Freedman R; Gonzalez de Leon C; Fishman A; Mante R; Hord M; Kudelka A
J Clin Oncol; 1995 Jul; 13(7):1584-8. PubMed ID: 7602347
[TBL] [Abstract][Full Text] [Related]
51. Docetaxel in the management of ovarian cancer.
Blagden SP; Kaye SB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518
[TBL] [Abstract][Full Text] [Related]
52. Sequential single agents as first-line chemotherapy for ovarian cancer: a strategy derived from the results of GOG-132.
Muggia FM
Int J Gynecol Cancer; 2003; 13 Suppl 2():156-62. PubMed ID: 14656273
[TBL] [Abstract][Full Text] [Related]
53. [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
Shimoya K; Kunishige I; Okuno Y; Hayashi S; Komura H; Arimoto Y; Otsuki Y
Gan To Kagaku Ryoho; 2001 Jun; 28(6):845-8. PubMed ID: 11432356
[TBL] [Abstract][Full Text] [Related]
54. [Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Misawa H; Ochiai K; Yasuda M; Tanaka T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():546-9. PubMed ID: 15535305
[No Abstract] [Full Text] [Related]
55. First-line chemotherapy for ovarian cancer - the controversy continues.
Kaye SB
Br J Cancer; 2002 Oct; 87(8):813-4. PubMed ID: 12373592
[No Abstract] [Full Text] [Related]
56. [Recent advances in ovarian cancer chemotherapy].
Hatae M; Onishi Y; Kume H; Maeda Y; Nakagawa S; Hokanishi H
Gan To Kagaku Ryoho; 1992 Oct; 19(12):1982-90. PubMed ID: 1384436
[TBL] [Abstract][Full Text] [Related]
57. Platinum alone for chemotherapy for ovarian cancer?
Johnston C
Lancet; 1998 Nov; 352(9140):1567-8. PubMed ID: 9843097
[No Abstract] [Full Text] [Related]
58. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel.
Rose PG; Smrekar M
Gynecol Oncol; 2003 Nov; 91(2):423-5. PubMed ID: 14599877
[TBL] [Abstract][Full Text] [Related]
59. Current clinical practices for ovarian cancers.
Harper P
Semin Oncol; 2002 Jun; 29(3 Suppl 8):3-6. PubMed ID: 12082646
[TBL] [Abstract][Full Text] [Related]
60. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?
du Bois A; Neijt JP; Thigpen JT
Ann Oncol; 1999; 10 Suppl 1():35-41. PubMed ID: 10219451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
